secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001193125-22-221288
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase posts corporate presentation; no specific financial or clinical data in filing
--------------------------------------------------------------------------------

- Presentation made available on company website on Aug 15, 2022, for investor presentations.
- Filing includes only cover page and disclaimer; full slide deck not reproduced in the 8-K.
- Presentation is dated 3Q 2022 and focuses on neurodegenerative disease and cancer therapeutics.
- No new financial results, guidance, or clinical milestones were disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/0001193125-22-221288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/d395011d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-221288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer